# Polypodium leucotomos (Phlebodium aureum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/polypodium-leucotomos-phlebodium-aureum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** South American
**Also Known As:** Phlebodium aureum, Calaguala, Fernblock, Golden polypody fern, PL extract

## Overview

Polypodium leucotomos extract delivers [photoprotect](/ingredients/condition/skin-health)ive effects primarily through phenolic compounds—including chlorogenic acid, caffeic acid, ferulic acid, and p-coumaric acid—that neutralize UV-induced [reactive oxygen species](/ingredients/condition/antioxidant), modulate p53 tumor-suppressor expression, and suppress TNF-α-mediated [inflammation](/ingredients/condition/inflammation). In a randomized, double-blind, placebo-controlled trial, oral supplementation at 480 mg/day for 60 days significantly reduced sunburn episodes (2 vs. 8 subjects; p=0.04) and increased the minimal erythema dose in 8 vs. 1 subject (p=0.01).

## Health Benefits

- **UV-Induced [Photoprotect](/ingredients/condition/skin-health)ion**: Phenolic constituents including chlorogenic acid and caffeic acid absorb and neutralize UV-generated free radicals in skin tissue, raising the minimal erythema dose and reducing clinically measurable erythema in human trials.
- **Antioxidant Defense Enhancement**: Oral administration has been shown to increase systemic blood antioxidant activity by approximately 30% in murine models, reflecting absorption and systemic distribution of phenolic metabolites that scavenge [reactive oxygen species](/ingredients/condition/antioxidant).
- **DNA Damage Prevention and p53 Upregulation**: The extract elevates p53 tumor-suppressor protein expression by approximately 63% in skin cells exposed to UV radiation, facilitating DNA repair and reducing mutagenic burden that underlies photocarcinogenesis.
- **[Anti-Inflammatory](/ingredients/condition/inflammation) Activity via TNF-α Suppression**: At a concentration of 0.01%, the extract decreases TNF-α production by 1.5–3-fold after 96 hours, dampening the UV-triggered inflammatory cascade responsible for erythema, edema, and chronic photodamage.
- **Polymorphous Light Eruption (PLE) Mitigation**: Weight-adjusted oral dosing of 720–1200 mg/day over two weeks significantly increased the number of UV-A and UV-B exposures required to provoke PLE reactions, indicating meaningful clinical benefit in photosensitive individuals.
- **Dermal Fibroblast Viability and Skin Repair Support**: At 1% concentration, the extract boosts fibroblast viability 2–5-fold and stimulates synthesis of structural skin proteins, supporting connective tissue integrity and post-UV recovery.
- **Pro-Apoptotic Regulation of Damaged Cells**: The extract upregulates pro-apoptotic proteins Bax and Bad while downregulating anti-apoptotic Bcl-xL, promoting selective clearance of UV-damaged keratinocytes and reducing the persistence of potentially pre-malignant cells.

## Mechanism of Action

Polypodium leucotomos extract exerts its [photoprotect](/ingredients/condition/skin-health)ive effects through a multi-target antioxidant and [immunomodulatory](/ingredients/condition/immune-support) mechanism: its constituent phenolic acids—particularly chlorogenic acid (≈3.7 mg/g in leaf tissue), caffeic acid, ferulic acid, and p-coumaric acid—directly scavenge hydroxyl radicals, superoxide anions, and singlet oxygen generated by UVA and UVB irradiation, thereby preventing [lipid peroxidation](/ingredients/condition/antioxidant) and oxidative DNA strand breaks. At the gene-expression level, the extract upregulates p53 tumor-suppressor protein in UV-exposed skin cells, triggering G1-phase cell-cycle arrest that allows DNA repair machinery to operate before replication; simultaneously, it shifts the Bcl-2 family balance by increasing pro-apoptotic Bax and Bad and decreasing anti-apoptotic Bcl-xL, enabling elimination of cells with irreparable photodamage. Inflammatory signaling is attenuated through suppression of TNF-α at concentrations as low as 0.01% and through modulation of growth factors including TGF-β, VEGF, and EGF, which collectively reduce mast cell degranulation, neutrophil infiltration, and [prostaglandin](/ingredients/condition/inflammation)-driven vasodilation in UV-exposed dermis. The net result is a systemic and topical reduction in UV-induced immunosuppression, erythema, and photo-aging pathways validated across both in vitro keratinocyte models and in vivo human supplementation trials.

## Clinical Summary

The most rigorously designed human trial used Fernblock®-derived extract at 480 mg/day (240 mg twice daily) for 60 days in a randomized, double-blind, placebo-controlled design, demonstrating statistically significant reductions in sunburn episodes (2 vs. 8 subjects; p=0.04), increases in minimal erythema dose response (8 vs. 1 subject; p=0.01), and decreases in UV-induced erythema (10 vs. 3 subjects; p<0.01). A second trial addressing polymorphous light eruption used weight-adjusted dosing (720 mg/day for subjects ≤70 kg; 1200 mg/day for subjects >70 kg) over 14 days, with the treated group requiring significantly greater cumulative UV-A and UV-B doses to provoke PLE reactions, confirming dose-response relevance. Both trials demonstrate consistent directional benefit in [photoprotect](/ingredients/condition/skin-health)ion, but undisclosed or small sample sizes, single research groups, and absence of long-term follow-up data constrain the overall confidence level to moderate. Effect sizes are clinically meaningful, and the safety profile across both trials was favorable, making the extract a credible adjunct photoprotective agent pending validation in larger, multicenter, pre-registered RCTs.

## Nutritional Profile

Polypodium leucotomos extract is not a significant source of macronutrients or classical micronutrients in supplemental doses; its bioactivity derives almost exclusively from its concentrated phytochemical fraction. The primary bioactive constituents are phenolic acids: chlorogenic acid at approximately 3.7 mg/g in leaf material, quinic acid comprising 0.4–0.9% of commercial aqueous extracts, ferulic acid, caffeic acid, p-coumaric acid, and vanillic acid at lower but pharmacologically relevant concentrations. Total phenolic content in standardized commercial extracts (Fernblock®) ranges from 0.6 to 1.3% w/w, representing the quality-control benchmark for [photoprotect](/ingredients/condition/skin-health)ive potency. Bioavailability of these phenolic acids after oral ingestion is influenced by gut microbiota [metabolism](/ingredients/condition/weight-management), first-pass hepatic conjugation, and intestinal absorption kinetics; absorbed metabolites circulate as glucuronide and sulfate conjugates that retain [antioxidant activity](/ingredients/condition/antioxidant) in the systemic circulation and skin tissue, though formal oral bioavailability pharmacokinetic studies specific to this extract remain limited.

## Dosage & Preparation

- **Oral Capsules (Standardized Extract)**: The most studied form; 240 mg twice daily (480 mg/day total) is the primary evidence-based dose for general [photoprotect](/ingredients/condition/skin-health)ion over 60-day periods, as used in the principal RCT.
- **Higher Oral Dosing for Photosensitive Individuals**: 720–1200 mg/day (weight-adjusted: ≤70 kg receives lower dose; >70 kg receives 1200 mg/day) used short-term (2 weeks) for polymorphous light eruption, with no serious adverse events reported.
- **Fernblock® Standardization**: Commercial extracts are standardized to total phenolic content of 0.6–1.3% w/w in aqueous extracts; consumers should verify standardization certificates when selecting products.
- **Topical Cream/Ointment**: Extract concentrations of 0.001–10 wt% in glycerin-based or emollient formulations applied to sun-exposed skin; 1 g dried plant material per 1–100 g base yields this range.
- **Timing Recommendation**: Oral dosing is typically taken 30–60 minutes before UV exposure to maximize systemic [antioxidant](/ingredients/condition/antioxidant) availability in skin; twice-daily dosing maintains more consistent plasma phenolic levels.
- **Traditional Aqueous Preparation**: Indigenous preparation involved decoction of dried aerial fronds; commercial aqueous extraction standardizes and concentrates this approach for reproducible dosing.

## Safety & Drug Interactions

Polypodium leucotomos extract demonstrated a favorable safety profile in the primary 60-day RCT at 480 mg/day, with no serious adverse events attributed to the supplement and only minor unrelated complaints reported; short-term use at up to 1200 mg/day similarly showed no significant adverse effects in available trial data. No clinically documented pharmacokinetic drug interactions have been formally established, though the extract's [antioxidant activity](/ingredients/condition/antioxidant) theoretically warrants caution when combined with photosensitizing medications (e.g., fluoroquinolones, tetracyclines, psoralens) given potential pharmacodynamic modulation of UV-response pathways. Specific contraindications have not been identified in the published literature; however, safety data in pregnancy and lactation are absent, and use during these states should be avoided until adequate studies are conducted. Long-term safety beyond 60 days has not been systematically evaluated in controlled trials, and third-party tested, standardized products are recommended to minimize risks from adulteration or inconsistent phenolic content.

## Scientific Research

The clinical evidence base for Polypodium leucotomos is modest but mechanistically coherent, consisting primarily of small randomized controlled trials and preclinical studies rather than large multicenter phase III investigations. A randomized, double-blind, placebo-controlled trial using 480 mg/day for 60 days demonstrated statistically significant reductions in sunburn episodes (p=0.04) and increases in minimal erythema dose (p=0.01), though sample size details were not fully disclosed, limiting power calculations and generalizability. A separate dose-escalation trial employing 720–1200 mg/day for two weeks in individuals with polymorphous light eruption showed that significantly more UV exposures were required to trigger reactions in treated subjects, providing replication of the [photoprotect](/ingredients/condition/skin-health)ive signal across different outcome measures. In vitro and murine studies supply robust mechanistic corroboration—including the 30% increase in blood [antioxidant activity](/ingredients/condition/antioxidant) and 63% p53 upregulation—but well-powered, independently replicated, long-term RCTs with standardized endpoints and full participant reporting remain necessary before definitive efficacy claims can be made.

## Historical & Cultural Context

Polypodium leucotomos has been used for centuries in Central American and South American indigenous medicine, particularly by populations in Honduras and neighboring regions, where infusions and decoctions of the fronds were prepared to treat [inflammatory](/ingredients/condition/inflammation) skin conditions including psoriasis, atopic dermatitis, and vitiligo. The plant's common Spanish-language name 'calaguala' reflects its widespread recognition across multiple Latin American cultures as a dermatological remedy, and it was traditionally harvested from forest understory environments and prepared as a hot-water extract drunk as a tea or applied topically as a poultice. Its introduction to European markets in the mid-20th century was catalyzed by clinical interest in its anti-psoriatic properties, leading eventually to the development of the standardized Fernblock® extract through Spanish pharmaceutical research in the 1990s. The transition from ethnobotanical folk remedy to a scientifically characterized nutraceutical represents one of the more complete trajectories from traditional use to modern [photoprotect](/ingredients/condition/skin-health)ive supplement in tropical fern pharmacognosy.

## Synergistic Combinations

Polypodium leucotomos extract is frequently combined with broad-spectrum topical sunscreen (SPF 30+) to provide complementary [photoprotect](/ingredients/condition/skin-health)ion—the sunscreen physically attenuates UV photon penetration while the extract neutralizes UV-generated [reactive oxygen species](/ingredients/condition/antioxidant) that bypass physical filters, creating additive defense across different mechanistic layers. Oral combination with vitamin C (ascorbic acid) and vitamin E (tocopherols) is a rationally supported antioxidant stack, as these vitamins regenerate oxidized phenolic intermediates and quench lipid peroxyl radicals in membrane compartments inaccessible to water-soluble polyphenols, potentially extending the antioxidant cascade initiated by PL extract's chlorogenic and caffeic acids. Preliminary data suggest that pairing with nicotinamide (vitamin B3) may further augment DNA repair capacity through complementary NAD⁺-dependent PARP-1 activation, although direct co-administration trials with Polypodium leucotomos have not yet been published.

## Frequently Asked Questions

### What is polypodium leucotomos used for?

Polypodium leucotomos extract is primarily used as an oral and topical photoprotective supplement to reduce UV-induced skin damage, including sunburn, erythema, and DNA oxidative injury. Its phenolic compounds—particularly chlorogenic acid, caffeic acid, and ferulic acid—neutralize reactive oxygen species generated by UVA and UVB radiation and suppress TNF-α-driven inflammation, making it a popular adjunct to conventional sunscreen in photosensitive individuals.

### How much polypodium leucotomos should I take daily?

The best-supported oral dose from clinical trials is 480 mg/day, taken as 240 mg twice daily, for up to 60 days to reduce UV-induced erythema and sunburn episodes. For polymorphous light eruption, higher doses of 720–1200 mg/day (weight-adjusted) have been used short-term (2 weeks) without reported serious side effects, though these doses should be used under medical guidance.

### Does polypodium leucotomos actually work as a sun protection supplement?

Yes, within the limits of available evidence: a randomized double-blind placebo-controlled trial found that 480 mg/day for 60 days significantly reduced sunburn episodes (2 vs. 8 subjects; p=0.04) and increased the minimal erythema dose in 8 vs. 1 subject (p=0.01). However, it should be considered a systemic adjunct to—not a replacement for—topical broad-spectrum sunscreen, as its photoprotection is partial and internally mediated.

### Is polypodium leucotomos safe to take long-term?

Available clinical data, primarily from a 60-day trial at 480 mg/day, indicate a good short-term safety profile with no serious adverse events attributable to the supplement. Long-term safety data beyond 60 days are currently lacking, no specific drug interactions have been formally documented, and safety in pregnancy or lactation has not been studied, making caution advisable in these populations until further research is available.

### What is the difference between polypodium leucotomos and Phlebodium aureum?

Polypodium leucotomos and Phlebodium aureum refer to the same tropical fern species; Phlebodium aureum is the currently accepted taxonomic name while Polypodium leucotomos is the older synonym that remains widely used in the nutritional supplement and clinical research literature. Both names refer to the same South and Central American epiphytic fern whose aqueous frond extracts provide standardized phenolic photoprotective compounds.

### Does polypodium leucotomos work better when taken before or after sun exposure?

Polypodium leucotomos should be taken regularly before sun exposure, typically 30 minutes to 2 hours prior, to allow absorption and establishment of systemic antioxidant defenses. The phenolic compounds need time to accumulate in skin tissue and enhance the minimal erythema dose, so consistent daily supplementation is more effective than reactive dosing after sun exposure has already occurred. Some research suggests taking it daily throughout the sunny season provides the most reliable photoprotection rather than sporadic use.

### Can polypodium leucotomos interact with sunscreen or other topical sun protection products?

No significant interactions have been documented between polypodium leucotomos and topical sunscreens; in fact, combining oral polypodium leucotomos with broad-spectrum SPF 30+ sunscreen may provide complementary protection through both systemic antioxidant and topical UV-blocking mechanisms. The oral photoprotective effect works through systemic absorption and free radical neutralization, while sunscreens work via topical UV absorption, making them compatible approaches. However, polypodium leucotomos should not be considered a replacement for sunscreen, as it does not physically block UV radiation.

### What clinical evidence supports polypodium leucotomos for skin protection in different skin types?

Human clinical trials have demonstrated that polypodium leucotomos raises the minimal erythema dose and reduces clinically measurable erythema across multiple populations, with the most robust evidence in fair-skinned and photosensitive individuals. The ingredient's chlorogenic acid and caffeic acid content absorb and neutralize UV-generated free radicals systemically, providing a mechanism of action that theoretically benefits all skin types, though darker skin types have fewer published trials. Most published research focuses on erythema prevention in sun-sensitive and photoaging-prone populations, with less data available for darker skin tones.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*